Gland Pharma has received approval from the USFDA to market a generic medication for breast cancer treatment, Eribulin Mesylate Injection. It’s expected to be the first generic approval in the market, with sales of around USD 92 million in the US.
Copyright © 2024 | WordPress Theme by MH Themes